Blogs

Be the first person to recommend this.
Today, the Centers for Medicare and Medicaid Services (CMS) released the proposed decision memo for the National Coverage Analysis (NCA) for CAR T-cell therapy. The proposal, found here , articulates how CMS would cover the advanced cancer therapy. We are in the process of reviewing the proposal and will be sending a second communication with a brief summary and draft talking points that can be utilized in your individual or organization’s response. ASBMT and other interested organizations have 30 days to review and comment.  CMS will issue final decision no later than 60 days after the conclusion of the 30-day comment period. ASBMT will be developing its ...
0 comments
Be the first person to recommend this.
By Mikaela VanMoorleghem, Education and Training Coordinator Foundation for the Accreditation of Cellular Therapy FACT Inspectors are Invited to Social Hour during TCT Meetings In honor of their dedication and service provided to the cell therapy community, FACT Inspectors are cordially invited to attend the FACT Inspector Social Hour on Friday, February 22, 2019 at the Hilton Americas-Houston Hotel, Room 335B from 5 pm – 6 pm. Light hors d'oeuvres and cocktails will be provided. -- International Delegates of the TCT Meetings Invited to Attend Special Session --  FACT International Accreditation The Foundation for the Accreditation of Cellular ...
0 comments
Be the first person to recommend this.
The discovery and development of chimeric antigen receptor T cells (CAR-T) cells for cancer immunotherapy has led to a paradigm shift in cancer management. Many professional medical societies have been closely involved in both the research and clinical aspects of CAR-T cells, however, ASBMT has taken a leadership role in various avenues of CAR-T cells including the society’s initiatives in health policy, clinical management and research. Recently, the ASBMT issued a position statement on grading of cytokine release syndrome (CRS) and neurological toxicity due to immune effector cells. Subsequently, the society released a statement on the clinical aspects of ...
0 comments
Be the first person to recommend this.
The Meet the Professor sessions lets attendees connect with people in the HCT field who currently work in academia. At this year's TCT Meetings of ASBMT and CIBMTR, there are eight sessions in total. One of the sessions will be presented by ASBMT’s Survivorship SIG and moderated by Dr. Scott Baker from the Fred Hutch Cancer Center and professor at the University of Washington, the event will feature panelists from small-to-medium sized cancer centers ASBMT sat down with Shahrukh Hashmi, MD, a member of the Survivorship SIG to discuss the event and why you should consider working in academia. ASBMT: Give us a brief bio of yourself. SHAHRUKH HASHMI: I ...
0 comments
Be the first person to recommend this.
In this month’s Pharmacy SIG Literature Update: Updates on commercial cellular therapy products, ECP for cGVHD, and more data for lenolidamide maintenance. Plus αβ haplos in pediatrics and much more! Literature summaries are provided as information only. Please refer to the original published articles for complete details on study methodology, results and discussion. ***        Must read. Landmark publication that affects practice **           Recommend reading. Secondary paper that adds to literature *             Consider reading. Cursory importance to the practice Cellular Therapy **Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety ...
0 comments
Be the first person to recommend this.
The Radiation Injury Treatment Network (RITN) will be hosting its 6 th biennial workshop titled – “Crisis in context: Minding the gaps in medical preparedness for a Rad/Nuke incident” in Arlington, VA on July 30-31, 2019. The workshop materials are up on www.RITN.net and online registration is open!  To learn more, see RITN's flyer . This workshop is intended for physicians and other healthcare providers, support staff, hospital and hospital system administrators, emergency managers, research scientists, and appropriate federal agency staff involved in radiation response and treatment of patients with radiation-induced bone marrow injury are invited. ...
0 comments
Be the first person to recommend this.
ASBMT is excited to announce the appointment of a new Director of Government Relations, Alycia Maloney.  Before joining ASBMT, Maloney served as the Health Policy Advisor and Legislative Counsel to Congressman Kevin Brady (R-TX). There she managed a legislative portfolio including health care, social security, human resources and appropriations. Before working in the House of Representatives, Maloney worked as a Research Associate with the Celgene Corporation, focusing in federal government relations. Maloney said she cannot wait to start working for ASBMT. "It is an honor to have the opportunity to work with such an incredible community of like minded individuals," ...
0 comments
Be the first person to recommend this.
As Shakespeare once wrote, “parting is such sweet sorrow.” It’s been an honor this past year to serve as ASBMT president. We’ve been able to accomplish so much—from advocating on Capitol Hill on behalf of CAR-T payments to meeting with those in the field of cellular transplantation internationally—and it’s only just the beginning for ASBMT. I’ve enjoyed meeting all of you and participating in some of ASBMT’s groundbreaking work this year. At the TCT Meetings of ASBMT and CIBMTR, I’ll be handing over the baton to Dr. Navneet Majhail, who is not only a friend but a great colleague. I have no doubt he will serve ASBMT well as president. Speaking of the TCT ...
0 comments
Be the first person to recommend this.
  The Latest on ASBMT’s Outreach on CAR-T It is still early in the new year, but ASBMT has been busy advancing potential reimbursement solutions for CAR-T therapy with key staff at the Centers for Medicare and Medicaid Services (CMS) and on Capitol Hill. The Society is following up with CMS leadership on the solutions outlined in the November 1 letter we sent with the American Society of Hematology. We hope to hold a meeting with agency leadership in the coming weeks to discuss these solutions in more detail. CMS will draft the FY 2020 Inpatient Prospective Payment System (IPPS) proposed rule in the coming months and we remain hopeful that it will include ...
0 comments
Be the first person to recommend this.
ASBMT always strives to be a leader in our field – and that includes tackling issues in an ever-changing landscape. That’s why ASBMT leadership is proud to announce the publication of our paper on consensus grading for IEC toxicities, “ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells.” Published in this very journal, the paper is authored by some of the best minds from around the world. Its inception began after CAR-T cell therapy started becoming one of the most encouraging forms of therapy for hematological malignancies. In recent years, there have been several different CAR-T products ...
0 comments
Be the first person to recommend this.
By Mikaela VanMoorleghem, Education and Training Coordinator for FACT Join FACT for Several Educational Events at the 2019 TCT Meetings! FACT Cellular Therapy Inspection and Accreditation Workshop - February 19, 2019 The blood and marrow transplantation field has been a leader in voluntarily improving quality through FACT accreditation.  Clinical programs are currently adapting to immune effector cellular therapy accreditation requirements and changes in the FACT-JACIE Seventh Edition Hematopoietic Cellular Therapy Standards. This workshop will address important topics in the cellular therapy field including: Overview of FACT Accreditation Processes ...
0 comments
Be the first person to recommend this.
The American Society for Blood and Marrow Transplantation is proud to offer a year-long program to provide training and develop the next generation of leaders in the field of blood and marrow transplantation and cellular therapy.  The program is intended for mid-career ASBMT members and will consist of a 1.5-day in person meeting, followed by a series of interactive webinars and graduation at the Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR the following year. Tuition, travel, housing and meal expenses will be covered by the society for course attendees. For the inaugural course, eight future leaders will be selected through a competitive ...
0 comments
Be the first person to recommend this.
By Syed Abutalib, MD Each month, the ASBMT Committee on Education releases a Self-Directed Learning Quiz. It's created for our ASBMT colleagues (physicians and practitioners) in the field of Hematology and Cellular Therapy with emphasis on "Basic Principles and Practices of Hematopoietic Cell Transplantation and Cell Therapy.” Answers to each question appear with evidence-based “non-exhaustive” peer-review commentary. Our aim is to provide you with a credible and freely available educational resource to enhance knowledge and clinical skills. Questions, answers and commentary are generated and critically reviewed by me, Syed Abutalib, MD; Mark R. Litzow, ...
0 comments
Be the first person to recommend this.
For the next three years, ASBMT is committing itself to four strategic goals, which will help the society attract more members, produce better education and research opportunities and create more brand recognition, among other things. These goals were approved as part of the ASBMT 2019-21 Strategic Plan, which outlines the values and goals for the society and its members. The society’s Board of Directors confirmed the plan at its December 2018 meeting. The goals will focus on: Brand Strength Education Recognition and Value Access and Knowledge Sharing All of the goals approved focus on creating more cohesion within the organization, specifically ...
0 comments
Be the first person to recommend this.
CAR-T Therapy:  Reflecting on our accomplishments and a look ahead ASBMT has devoted significant time and resources to protecting appropriate patient access to CAR-T therapy and improving provider reimbursement for the therapy in 2018. There is still a great deal that must be done in the New Year, but as 2018 comes to a close, I want to take this opportunity to reflect on all the organization has been able to accomplish. Many of you have been engaged in the research on CAR-T, delivered the therapy as part of clinical trials, and practice at the centers delivering this therapy to patients. Your expertise has been integral to the Association’s work and allowed ...
0 comments
Be the first person to recommend this.
Literature summaries are provided as information only. Please refer to the original published articles for complete details on study methodology, results and discussion. ***        Must read. Landmark publication that affects practice **           Recommend reading. Secondary paper that adds to literature *             Consider reading. Cursory importance to the practice In this month’s Pharmacy SIG Literature Update: Does CMV reactivation reduce relapse rates? Immune reconstitution post ablative transplants using ATLG, RIC with FLAMSA vs BuFlu, and preemptive azacitidine for MRD positivity.  And more!   Allogeneic Transplant *Gooptu M, Kim ...
0 comments
Be the first person to recommend this.
To many, the Beyond Fundamentals of HCT course offered at the TCT Meetings of ASBMT & CIBMTR isn’t your average “conference course.” For more than 10 years, registrants of the course are invited to a two-day group event that is an extensive training program designed to provide practitioners with the skills required to care for patients undergoing HCT. It’s aimed to help pharmacists, pharmacy students and residents, physicians, advanced practice providers and nurses. Topics range from conditioning regimens to long-term care and survivorship. The course offers great insight and experience for those looking to be on top of their game, specifically those ...
0 comments
Be the first person to recommend this.
For many people, the New Year brings a time of reflection: How can I better myself? At ASBMT, we are constantly asking how to improve what we do and how we help those around the world in the field of cellular transplantation. Recently, we started focusing on our international partnerships, and much to our delight, it’s been well received. It’s always so exciting to connect with our international partners. Each of us come from different cultural and political landscapes, and each of us approach the BBMT field in our own unique way. Being able to show the work we do on a daily basis, and learn from the work of others, only advances the entire community forward. ...
0 comments
Be the first person to recommend this.
By ASBMT President, Dr. John F. DiPersio It’s hard to believe that 2018 is almost over. It’s been both a productive and challenging year for ASBMT, but overall, we’re proud of the work we’ve done with our members and on behalf of them. Let’s take a look back and see at some of the incredible things we accomplished in 2018. The TCT Meetings of ASBMT and CIBMTR We had a record-breaking number of attendants at our meeting this year in Salt Lake City. Not only that, this was the first year under our new rebranded name, the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR (also known as the TCT Meetings). Formerly called the BMT Tandem ...
0 comments
Be the first person to recommend this.
ASBMT, the American Society of Hematology, the American Cancer Society-Cancer Action Network, the Leukemia and Lymphoma Society, the Lymphoma Research Foundation and the Personalized Medicine Coalition sponsored a journalist briefing on CAR-T on November 16 in Washington, D.C. A patient shared his experience receiving CAR-T at the University of Maryland and how the procedure saved his life when he had exhausted treatment options. His doctor, Dr. Aaron Rapaport, gave a presentation on the mechanics of CAR-T and discussed the process that the University of Maryland recently completed to become a Yescarta-certified facility. Meghan Gutierrez from the Lymphoma ...
0 comments